Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria

Ipsen delivers FY and Q4 2022 results – A word from CEO David Loew